Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group

The objective of this phase I/II study was to examine the efficacy and toxicity profile of temozolomide (TMZ) plus nimustine (ACNU). Patients who had received a standard radiotherapy with one or two previous chemo-regimens were enrolled. In phase I, the maximum-tolerated dose (MTD) by TMZ (150 mg/m(...

Descripción completa

Detalles Bibliográficos
Autores principales: AOKI, Tomokazu, ARAKAWA, Yoshiki, UEBA, Tetsuya, ODA, Masashi, NISHIDA, Namiko, AKIYAMA, Yukinori, TSUKAHARA, Tetsuya, IWASAKI, Koichi, MIKUNI, Nobuhiro, MIYAMOTO, Susumu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japan Neurosurgical Society 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5243161/
https://www.ncbi.nlm.nih.gov/pubmed/27725524
http://dx.doi.org/10.2176/nmc.oa.2016-0162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5243161/
https://www.ncbi.nlm.nih.gov/pubmed/27725524
http://dx.doi.org/10.2176/nmc.oa.2016-0162

Ejemplares similares